影响雷珠单抗治疗CRVO继发黄斑水肿患者的短期效果的多因素分析  

Multivariate Analysis of the Short-term Effects of Ranibizumab in the Treatment of Patients with Macular Edema Secondary to CRVO

作　　者：袁钊华 郑元建 罗洁贞 YUAN Zhaohua;ZHENG Yuanjian;LUO Jiezhen(Department of Ophthalmology,the Sixth People’s Hospital of Huizhou,Huizhou City,Guangdong Province 516211)

机构地区：[1]广东省惠州市第六人民医院眼科,516211

出　　处：《医学理论与实践》2021年第11期1814-1816,共3页The Journal of Medical Theory and Practice

基　　金：惠州市科技计划项目(2020Y328)。

摘　　要：目的:分析雷珠单抗治疗CRVO继发黄斑水肿患者的短期效果的影响因素。方法:以我院2017年1月—2020年1月收治采用雷珠单抗治疗的120例(120眼)CRVO继发黄斑水肿患者作为研究对象,观察其治疗90d后的BCVA以及CRT变化,同时分析影响其短期效果的相关因素。结果:120例患者治疗30d后的CRT以及BCVA均值分别为(743.46±107.84)μm和(1.02±0.38)LogMAR;治疗90d后的CRT以及BCVA均值分别为(405.09±119.56)μm和(1.15±0.22)LogMAR。所有患者治疗后,其视力均显著提高,同时黄斑水肿均有明显消退,其中54.17%患者的黄斑水肿于治疗30d后消退,所有患者均未发生并发症。年龄大、CRT下降明显者以及CME消退者的短期疗效要更优(P<0.05),同时多因素Logistic回归分析结果显示导致患者治疗90d后CRT恢复不良的独立危险因素为年龄和基线CRT(P<0.05)。结论:对于CRVO继发黄斑水肿患者,雷珠单抗治疗效果理想,不仅可以显著提高患者的BCVA,而且还有利于进一步降低CRT,年龄以及基线CRT是影响其短期效果的独立危险因素。Objective:To analyze the factors affecting the short-term effect of ranibizumab in the treatment of patients with macular edema secondary to CRVO.Methods:120 patients(120 eyes)with CRVO secondary to macular edema who were treated with ranibizumab in our hospital from January 2017 to January 2020 were taken as the research objects.The changes in BCVA and CRT after 90 days of treatment were observed and analyzed related factors affecting its short-term effect.Results:The mean values of CRT and BCVA of 120 patients after 30 days of treatment were(743.46±107.84)μm and(1.02±0.38)LogMAR,respectively;the mean values of CRT and BCVA after 90 days of treatment were(405.09±119.56)μm and(1.15±0.22)LogMAR,respectively.After treatment,the visual acuity of all patients was significantly improved,and the macular edema was significantly resolved.Among them,54.17%of the macular edema resolved after 30 days of treatment,and no complications occurred in all patients.The short-term curative effect was better in those with older age,significantly decreased CRT,and CME regression(P<0.05).At the same time,multivariate Logistic regression analysis showed that the independent risk factors for poor CRT recovery after 90 days of treatment were age and baseline CRT(P<0.05).Conclusion:For patients with macular edema secondary to CRVO,ranibizumab has an ideal therapeutic effect.It can not only significantly increase the patient’s BCVA,but also help to further reduce CRT.Age and baseline CRT are independent risk factors that affect their short-term effects.

关 键 词：视网膜中央静脉阻塞 黄斑水肿 雷珠单抗 黄斑中心视网膜厚度 最佳矫正视力 

分 类 号：R774.1[医药卫生—眼科]